NeoGenomics, Inc. Payments to Acquire Debt Securities, Available-for-sale
NeoGenomics, Inc. (NEO) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-02-17
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was $0.00.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $0.00.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $6.76M, a 93.08% decline from fiscal 2022.
- NeoGenomics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $97.61M, a 50.40% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 10-K · filed 2026-02-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $6.76M 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $6.76M 10-Q · filed 2024-11-05 | $30.39M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $6.76M 10-Q · filed 2024-07-30 | $30.39M derived: sum of 3 quarters · filed 2025-02-18 | $48.03M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $6.76M 10-Q · filed 2024-04-30 | $30.39M derived: sum of 2 quarters · filed 2025-02-18 | $48.03M derived: sum of 3 quarters · filed 2025-02-18 | $88.19M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $23.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $41.27M derived: sum of 2 quarters · filed 2025-02-18 | $81.44M derived: sum of 3 quarters · filed 2025-02-18 | $97.61M 10-K · filed 2025-02-18 |
| 2022-09-30 | $17.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $57.81M derived: sum of 2 quarters · filed 2023-11-06 | $73.97M 10-Q · filed 2023-11-06 | $89.80M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $40.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $56.33M 10-Q · filed 2023-08-08 | $72.16M derived: sum of 3 quarters · filed 2024-02-20 | $90.35M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $16.17M 10-Q · filed 2023-05-09 | $32.00M derived: sum of 2 quarters · filed 2024-02-20 | $50.19M derived: sum of 3 quarters · filed 2024-02-20 | $75.18M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $15.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $34.02M derived: sum of 2 quarters · filed 2024-02-20 | $59.02M derived: sum of 3 quarters · filed 2024-02-20 | $196.79M 10-K · filed 2024-02-20 |
| 2021-09-30 | $18.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $43.19M derived: sum of 2 quarters · filed 2022-11-08 | $180.96M 10-Q · filed 2022-11-08 | $200.67M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $24.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $162.77M 10-Q · filed 2022-08-09 | $182.47M derived: sum of 3 quarters · filed 2023-02-24 | $235.87M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $137.78M 10-Q · filed 2022-05-09 | $157.48M derived: sum of 2 quarters · filed 2023-02-24 | $210.88M derived: sum of 3 quarters · filed 2023-02-24 | $210.88M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $19.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $73.10M derived: sum of 2 quarters · filed 2023-02-24 | $73.10M derived: sum of 3 quarters · filed 2023-02-24 | $73.10M 10-K · filed 2023-02-24 |
| 2020-09-30 | $53.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $53.40M derived: sum of 2 quarters · filed 2021-11-04 | $53.40M 10-Q · filed 2021-11-04 | $53.40M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-02-25 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |